Stocks
ChemoCentryx Financial Statements (CCXI) |
||||||||||
| ChemoCentryxsmart-lab.ru | % | 2017 | 2018 | 2019 | 2020 | 2021 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 12.03.2018 | 11.03.2019 | 10.03.2020 | 01.03.2021 | 01.03.2022 | 08.08.2022 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 82.5 | 42.9 | 36.0 | 64.9 | 32.2 | 37.5 | |||
| Operating Income, bln rub | 16.5 | -40.3 | -58.3 | -55.2 | -134.5 | -136.2 | ||||
| EBITDA, bln rub | ? | 18.3 | -36.2 | -51.7 | -51.9 | -131.3 | -131.9 | |||
| Net profit, bln rub | ? | 17.9 | -38.0 | -55.5 | -55.4 | -129.1 | -129.5 | |||
| OCF, bln rub | ? | 4.88 | 16.4 | -70.1 | -81.1 | -75.6 | -53.5 | |||
| CAPEX, bln rub | ? | 0.723 | 0.838 | 0.790 | 15.4 | 19.0 | 5.47 | |||
| FCF, bln rub | ? | 4.16 | 15.6 | -70.9 | -96.6 | -94.6 | -59.0 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 66.0 | 83.1 | 94.3 | 120.1 | 162.1 | 168.2 | ||||
| Cost of production, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.302 | 1.31 | ||||
| R&D, bln rub | 49.5 | 62.7 | 70.3 | 77.9 | 83.0 | 70.6 | ||||
| Interest expenses, bln rub | 0.004 | 1.22 | 2.15 | 2.64 | 2.70 | 6.60 | ||||
| Assets, bln rub | 189.3 | 183.3 | 209.1 | 518.9 | 425.7 | 419.4 | ||||
| Net Assets, bln rub | ? | 79.3 | 14.7 | 66.0 | 385.6 | 286.1 | 236.5 | |||
| Debt, bln rub | 91.9 | 168.6 | 21.3 | 25.2 | 4.72 | 72.0 | ||||
| Cash, bln rub | 127.3 | 177.0 | 172.8 | 436.6 | 264.5 | 328.6 | ||||
| Net debt, bln rub | -35.3 | -8.40 | -151.5 | -411.3 | -259.8 | -256.6 | ||||
| Ordinary share price, rub | 5.95 | 10.9 | 39.6 | 61.9 | 36.4 | 51.9 | ||||
| Number of ordinary shares, mln | 48.4 | 49.8 | 56.9 | 65.7 | 65.7 | 71.2 | ||||
| Market cap, bln rub | 288 | 543 | 2 250 | 4 067 | 2 392 | 3 696 | ||||
| EV, bln rub | ? | 253 | 535 | 2 099 | 3 656 | 2 132 | 3 440 | |||
| Book value, bln rub | 79 | 15 | 66 | 386 | 286 | 237 | ||||
| EPS, rub | ? | 0.37 | -0.76 | -0.98 | -0.84 | -1.96 | -1.82 | |||
| FCF/share, rub | 0.09 | 0.31 | -1.25 | -1.47 | -1.44 | -0.83 | ||||
| BV/share, rub | 1.64 | 0.30 | 1.16 | 5.87 | 4.36 | 3.32 | ||||
| EBITDA margin, % | ? | 22.2% | -84.5% | -143.8% | -80.0% | -407.5% | -351.6% | |||
| Net margin, % | ? | 21.6% | -88.6% | -154.3% | -85.3% | -400.5% | -345.2% | |||
| FCF yield, % | ? | 1.44% | 2.87% | -3.15% | -2.37% | -3.96% | -1.60% | |||
| ROE, % | ? | 22.5% | -257.6% | -84.1% | -14.4% | -45.1% | -54.8% | |||
| ROA, % | ? | 9.43% | -20.7% | -26.5% | -10.7% | -30.3% | -30.9% | |||
| P/E | ? | 16.1 | -14.3 | -40.6 | -73.5 | -18.5 | -28.5 | |||
| P/FCF | 69.3 | 34.8 | -31.7 | -42.1 | -25.3 | -62.7 | ||||
| P/S | ? | 3.49 | 12.7 | 62.6 | 62.7 | 74.2 | 98.5 | |||
| P/BV | ? | 3.63 | 36.9 | 34.1 | 10.5 | 8.36 | 15.6 | |||
| EV/EBITDA | ? | 13.8 | -14.8 | -40.6 | -70.4 | -16.2 | -26.1 | |||
| Debt/EBITDA | -1.93 | 0.23 | 2.93 | 7.92 | 1.98 | 1.95 | ||||
| R&D/CAPEX, % | 6 846% | 7 486% | 8 896% | 505.4% | 436.3% | 1 290% | ||||
| CAPEX/Revenue, % | 0.88% | 1.95% | 2.20% | 23.7% | 59.0% | 14.6% | ||||
| ChemoCentryx shareholders | ||||||||||
